

## Select High Cost, Orphan, and Accelerated Approval Drugs

This data table provides interim coverage information for a list of select drugs, including high cost drugs, orphan drugs, and other drugs approved under a Food and Drug Administration (FDA) accelerated approval pathway. These drugs are covered for FDA-approved indications when medically necessary. Information about a drug’s FDA-approved indication(s) can be found on the FDA website. Specific interim billing and coverage information for each drug can be found in the table below. These drugs and the billing or coverage of ancillary services related to these drugs are subject to all existing ForwardHealth coverage and billing policy, which may be found in the [ForwardHealth Online Handbook](#) on the ForwardHealth Portal.

If a drug listed below has established drug-specific clinical criteria, refer to the [Services Requiring Prior Authorization](#) chapter of the Prior Authorization section of the Pharmacy service area of the Online Handbook on the Portal for information about the clinical criteria and directions for submitting prior authorization (PA) requests.

If a drug listed below requires PA to support that use is for an FDA-approved indication and is medically necessary as defined by Wis. Admin. Code § DHS 101.03(96m) but does not have drug-specific clinical criteria, PA requests must be submitted using Section VII (Clinical Information for Other Drug Requests) of the Prior Authorization/Drug Attachment (PA/DGA) form, F-11049 (07/2016), and the Prior Authorization Request Form (PA/RF), F-11018 (05/13). Medical records (e.g., chart notes, laboratory values) must be submitted along with the PA request to support that use is both medically necessary and for an FDA-approved indication. The drug must be prescribed in a dose and manner consistent with FDA-approved product labeling.

For specific questions about the billing or coverage of high cost, orphan, and accelerated approval drugs listed in this data table, providers may contact Provider Services at 800-947-9627 or email [DHSOrphanDrugs@dhs.wisconsin.gov](mailto:DHSOrphanDrugs@dhs.wisconsin.gov).

*Note:* The information contained in this data table is subject to change, and it is the provider’s responsibility to remain up-to-date with the information included in this data table.

Effective 9/1/2021

<p>ABECMA idecabtagene</p>	<ul style="list-style-type: none"> <li>○ Abecma does not require PA.</li> <li>○ Abecma will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines).</li> <li>○ Abecma will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Abecma, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
--------------------------------	---

<p>AMONDYS 45 casimersen</p>	<ul style="list-style-type: none"> <li>○ Amondys 45 requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Amondys 45 is approved, Amondys 45 will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Amondys 45, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>BREYANZI lisocabtagene maraleucel</p>	<ul style="list-style-type: none"> <li>○ Breyanzi does not require PA.</li> <li>○ Breyanzi will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines).</li> <li>○ Breyanzi will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Breyanzi, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>CRYSVITA burosumab-twza</p>	<ul style="list-style-type: none"> <li>○ Crysvita requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Crysvita is approved, Crysvita will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Crysvita, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>DOJOLVI triheptanoin</p>	<ul style="list-style-type: none"> <li>○ Dojolvi requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ A PA/DGA form Section VII must be submitted with the following clinical documentation and medical records to support the member's medical condition and outline the member's current treatment plan. <ul style="list-style-type: none"> <li>○ Member has a confirmed diagnosis of a long-chain fatty acid oxidation disorder.</li> <li>○ Dietary assessment and plan which includes member's height, weight and estimated total daily caloric intake.</li> <li>○ Complete dietary treatment plan, including a copy of the prescription order for Dojolvi. The treatment plan must include the target daily dosage of Dojolvi as a percentage of total daily caloric intake.  Note: Dojolvi is prescribed in mls and the recommended target daily dosage is up to 35% of the member's total daily caloric intake divided into at least four doses.</li> </ul> </li> <li>○ If a PA request for Dojolvi is approved, Dojolvi will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Dojolvi, providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>ENDARI L-glutamine oral powder</p>	<ul style="list-style-type: none"> <li>○ Endari requires PA; established clinical criteria for Endari can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Endari is approved, Endari will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Endari, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>

<p>EVRYSDI risdiplam</p>	<ul style="list-style-type: none"> <li>○ Evrysdi requires PA; established clinical criteria for Evrysdi can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Evrysdi is approved, Evrysdi will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Evrysdi, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>EXONDYS 51 eteplirsen</p>	<ul style="list-style-type: none"> <li>○ Exondys 51 requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Exondys 51 is approved, Exondys 51 will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Exondys 51, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>FIRDAPSE amifampridine</p>	<ul style="list-style-type: none"> <li>○ Firdapse requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Firdapse is approved, Firdapse will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Firdapse, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>GAMIFANT emapalumab-lzsg</p>	<ul style="list-style-type: none"> <li>○ Gamifant requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Gamifant is approved, Gamifant will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Gamifant, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>JYNARQUE tolvaptan</p>	<ul style="list-style-type: none"> <li>○ Jynarque requires PA; established clinical criteria for Jynarque can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Jynarque is approved, Jynarque will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Jynarque, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>KYMRIAH tisagenlecleucel</p>	<ul style="list-style-type: none"> <li>○ Kymriah does not require PA.</li> <li>○ Kymriah will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines).</li> <li>○ Kymriah will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Kymriah, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>LUXTURNA voretigene neparvovec- rzym</p>	<ul style="list-style-type: none"> <li>○ Luxturna requires PA; established clinical criteria for Luxturna can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Luxturna is approved, Luxturna will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Luxturna, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>

<p><b>MEPSEVII</b> vestronidase alfa-vjvk</p>	<ul style="list-style-type: none"> <li>○ Mepsevii requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Mepsevii is approved, Mepsevii will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Mepsevii, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>ONPATTRO</b> patisiran</p>	<ul style="list-style-type: none"> <li>○ Onpattro does not require PA.</li> <li>○ Onpattro will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines).</li> <li>○ Onpattro will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Onpattro, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>ORLADEYO</b> berotralstat</p>	<ul style="list-style-type: none"> <li>○ Orladeyo requires PA; established clinical criteria for Orladeyo can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Orladeyo is approved, Orladeyo will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Orladeyo, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>OXERVATE</b> cenegermin</p>	<ul style="list-style-type: none"> <li>○ Oxervate does not require PA.</li> <li>○ Oxervate will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines).</li> <li>○ Oxervate will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Oxervate, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>PALYNZIQ</b> pegvaliase-pqpz</p>	<ul style="list-style-type: none"> <li>○ Palynziq requires PA; established clinical criteria for Palynziq can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Palynziq is approved, Palynziq will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Palynziq, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>RUZURGI</b> amifampridine</p>	<ul style="list-style-type: none"> <li>○ Ruzurgi requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Ruzurgi is approved, Ruzurgi will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Ruzurgi, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>SPINRAZA</b> nusinersen</p>	<ul style="list-style-type: none"> <li>○ Spinraza requires PA; established clinical criteria for Spinraza can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Spinraza is approved, Spinraza will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Spinraza, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>

<p><b>TAKHZYRO</b> lanadelumab-flyo</p>	<ul style="list-style-type: none"> <li>○ Takhzyro requires PA; established clinical criteria for Takhzyro can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Takhzyro is approved, Takhzyro will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Takhzyro, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>TECARTUS</b> brexucabtagene</p>	<ul style="list-style-type: none"> <li>○ Tecartus does not require PA.</li> <li>○ Tecartus will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines).</li> <li>○ Tecartus will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Tecartus, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>TEGSEDI</b> inotersen</p>	<ul style="list-style-type: none"> <li>○ Tegsedi does not require PA.</li> <li>○ Tegsedi will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines).</li> <li>○ Tegsedi will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Tegsedi, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>VILTEPSO</b> viltolarsen</p>	<ul style="list-style-type: none"> <li>○ Viltepsos requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Viltepsos is approved, Viltepsos will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Viltepsos, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>VYONDYS 53</b> golodirsen</p>	<ul style="list-style-type: none"> <li>○ Vyondys 53 requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Vyondys 53 is approved, Vyondys 53 will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Vyondys 53, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p><b>YESCARTA</b> axicabtagene ciloleucel</p>	<ul style="list-style-type: none"> <li>○ Yescarta does not require PA.</li> <li>○ Yescarta will only be reimbursed when used for an FDA-approved indication and where use is appropriate with regard to generally accepted standards of medical practice (i.e., consistent with relevant professional society guidelines; e.g., NCCN guidelines).</li> <li>○ Yescarta will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Yescarta, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>

<p>ZOKINVY lonafarnib</p>	<ul style="list-style-type: none"> <li>○ Zokinvy requires PA to support that use is for an FDA-approved indication and is medically necessary.</li> <li>○ If a PA request for Zokinvy is approved, Zokinvy will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Zokinvy, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>
<p>ZOLGENSMA onasemnogene abeparvovec-xioi</p>	<ul style="list-style-type: none"> <li>○ Zolgensma requires PA; established clinical criteria for Zolgensma can be found in the Online Handbook on the Portal.</li> <li>○ If a PA request for Zolgensma is approved, Zolgensma will be covered under the pharmacy benefit.</li> <li>○ To bill ForwardHealth for Zolgensma, pharmacy providers should submit a pharmacy noncompound drug claim.</li> </ul>

*Note:* Pharmacy providers who receive Medicaid reimbursement for select high cost, orphan, and accelerated approval drugs may be subject to audit at any time. Pharmacy providers are required to retain relevant documentation supporting adherence to ForwardHealth program requirements and produce it for and/or submit it to ForwardHealth upon request. ForwardHealth may deny or recoup payment for services that fail to meet program requirements.